Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03473236 · ClinicalTrials.gov registry record · Phase 1
Phase 1A Safety Trial of Inhaled PK10571 (GB002)
A Phase 1 study, sponsored by GB002, Inc., a wholly owned subsidiary of Gossamer Bio.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT03473236: Completed Phase 1 study, sponsored by GB002, Inc., a wholly owned subsidiary of Gossamer Bio.
NCT03473236 is a Phase 1 study that has completed, run by GB002, Inc., a wholly owned subsidiary of Gossamer Bio. The registered enrollment target is 66 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (10% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03473236, a Phase 1 study, has completed, sponsored by GB002, Inc., a wholly owned subsidiary of Gossamer Bio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
This is a phase 1A randomized double blind placebo controlled single ascending dose and multiple ascending dose trial of inhaled PK10571 (GB002) in healthy adult subjects.
Primary Outcome
An adverse event (AE) is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A serious AE (SAE) is one that, in the view of either the investigator or Sponsor, results in any of the following outcomes: death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a co
Interventions
- DRUG Placebo
- DEVICE Generic Dry Powder Inhaler
- DRUG GB002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2017-09-06 |
| Est. Completion | 2018-12-03 |
| Phase | Phase 1 |
What the finished NCT03473236 record still lists
NCT03473236 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (10% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03473236 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03473236 about?
NCT03473236 is a clinical study titled "Phase 1A Safety Trial of Inhaled PK10571 (GB002)". This is a phase 1A randomized double blind placebo controlled single ascending dose and multiple ascending dose trial of inhaled PK10571 (GB002) in healthy adult subjects.
What is the current status of trial NCT03473236?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2017-09-06. Estimated completion is 2018-12-03.
What interventions are being tested in trial NCT03473236?
The interventions under investigation include: Placebo (DRUG), Generic Dry Powder Inhaler (DEVICE), GB002 (DRUG).
Who is sponsoring clinical trial NCT03473236?
This trial is sponsored by GB002, Inc., a wholly owned subsidiary of Gossamer Bio, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03473236's enrollment target sits among peer trials
66 786th of 2000 higher than 1,203 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI